News from the healthcare data industry
Centers for Disease Control and Prevention Continues Critical Work to Modernize Data ManagementApril 15, 2022 06:59 AM Eastern Daylight Time DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. (NYSE:PLTR) today announced an extension and...
Harriet Unsworth outlines her role in updating our evidence standards framework for digital health technologies. She also explains how you can share your views as part of our consultation. 12...
The NICE Strategy 2021 to 2026 states our ambition to use real-world data to resolve gaps in knowledge and drive forward access to innovations for patients. To help deliver on...
NHS England is laying plans for the development of a federated data platform. It has published a prior information notice for potential suppliers, indicating that the procurement could have a total value...
Posted 31 March 2022 | By Ferdous Al-Faruque While the US Food and Drug Administration (FDA) began the process of modernizing its IT systems before the COVID-19 pandemic, the crisis accelerated...
March 30, 2022 06:00 PM Eastern Daylight Time AMSTERDAM–(BUSINESS WIRE)–IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today...
Senior national security leaders to advise its US Government businessMarch 30, 2022 06:59 AM Eastern Daylight Time DENVER–(BUSINESS WIRE)–Palantir Technologies Inc. today unveiled members of its inaugural Palantir Federal Advisory...
The agency’s accelerated approval program for certain drugs has come under intense scrutiny because some medicines stay on the market despite limited evidence that they work. Read more at the...
22 Mar 2022 Francesca Bruce@ScripFrancesca Francesca.bruce@informa.com Executive Summary England’s health technology appraisal body, NICE, will publish a framework that will help it deliver on its ambition to use real-world evidence to...
When inspecting clinical trials that incorporate real-world data, the UK medicines regulator says that its good clinical practice (GCP) inspectors expects sponsors to be able to demonstrate that the RWD...